Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report

Caterina Lanna,* Gaia Maria Cesaroni,* Sara Mazzilli, Luca Bianchi, Elena Campione Dermatologic Unit, University of Rome Tor Vergata, Rome, Italy*These authors contributed equally to this workCorrespondence: Caterina LannaDermatologic Unit, Department of Systems Medicine, University of Rome Tor Verg...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lanna C, Cesaroni GM, Mazzilli S, Bianchi L, Campione E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	psoriasis diabetes pde4-inhibitor Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/68e9d06333ca45658b0367822abe8b4a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:68e9d06333ca45658b0367822abe8b4a
record_format	dspace
spelling	oai:doaj.org-article:68e9d06333ca45658b0367822abe8b4a2021-12-02T06:40:57ZSmall Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report1178-7007https://doaj.org/article/68e9d06333ca45658b0367822abe8b4a2019-12-01T00:00:00Zhttps://www.dovepress.com/small-molecules-big-promises-improvement-of-psoriasis-severity-and-glu-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Caterina Lanna,* Gaia Maria Cesaroni,* Sara Mazzilli, Luca Bianchi, Elena Campione Dermatologic Unit, University of Rome Tor Vergata, Rome, Italy*These authors contributed equally to this workCorrespondence: Caterina LannaDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 81, Rome 00133, ItalyEmail caterinalanna.cl@gmail.comAbstract: Psoriasis is a common inflammatory skin condition frequently associated with cardiometabolic diseases such as diabetes. Indeed, the state of systemic inflammation typical of psoriasis leads to an increase in the level of IL-1, IL-6 and TNF-alpha which may cause a reduced sensitivity to insulin and, ultimately, can lead to type 2 diabetes mellitus. Particularly, the derangement of PDE4-cAMP signaling has a critical role in disordered glucose and lipid metabolism. Apremilast, as a selective inhibitor of PDE4-cAMP signalling, represents an innovative therapeutic strategy for psoriasis. Here, we report a case of a patient affected by psoriasis and diabetes, who – after using Apremilast – improved his glucose metabolism as well as his need of anti-diabetic drugs and his psoriasis. This suggests that, in addition to its role against psoriasis, Apremilast may even act as a metabolic modulator.Keywords: psoriasis, diabetes, PDE4-inhibitorLanna CCesaroni GMMazzilli SBianchi LCampione EDove Medical Pressarticlepsoriasisdiabetespde4-inhibitorSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 2685-2688 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	psoriasis diabetes pde4-inhibitor Specialties of internal medicine RC581-951
spellingShingle	psoriasis diabetes pde4-inhibitor Specialties of internal medicine RC581-951 Lanna C Cesaroni GM Mazzilli S Bianchi L Campione E Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
description	Caterina Lanna,* Gaia Maria Cesaroni,* Sara Mazzilli, Luca Bianchi, Elena Campione Dermatologic Unit, University of Rome Tor Vergata, Rome, Italy*These authors contributed equally to this workCorrespondence: Caterina LannaDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 81, Rome 00133, ItalyEmail caterinalanna.cl@gmail.comAbstract: Psoriasis is a common inflammatory skin condition frequently associated with cardiometabolic diseases such as diabetes. Indeed, the state of systemic inflammation typical of psoriasis leads to an increase in the level of IL-1, IL-6 and TNF-alpha which may cause a reduced sensitivity to insulin and, ultimately, can lead to type 2 diabetes mellitus. Particularly, the derangement of PDE4-cAMP signaling has a critical role in disordered glucose and lipid metabolism. Apremilast, as a selective inhibitor of PDE4-cAMP signalling, represents an innovative therapeutic strategy for psoriasis. Here, we report a case of a patient affected by psoriasis and diabetes, who – after using Apremilast – improved his glucose metabolism as well as his need of anti-diabetic drugs and his psoriasis. This suggests that, in addition to its role against psoriasis, Apremilast may even act as a metabolic modulator.Keywords: psoriasis, diabetes, PDE4-inhibitor
format	article
author	Lanna C Cesaroni GM Mazzilli S Bianchi L Campione E
author_facet	Lanna C Cesaroni GM Mazzilli S Bianchi L Campione E
author_sort	Lanna C
title	Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
title_short	Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
title_full	Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
title_fullStr	Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
title_full_unstemmed	Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
title_sort	small molecules, big promises: improvement of psoriasis severity and glucidic markers with apremilast: a case report
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/68e9d06333ca45658b0367822abe8b4a
work_keys_str_mv	AT lannac smallmoleculesbigpromisesimprovementofpsoriasisseverityandglucidicmarkerswithapremilastacasereport AT cesaronigm smallmoleculesbigpromisesimprovementofpsoriasisseverityandglucidicmarkerswithapremilastacasereport AT mazzillis smallmoleculesbigpromisesimprovementofpsoriasisseverityandglucidicmarkerswithapremilastacasereport AT bianchil smallmoleculesbigpromisesimprovementofpsoriasisseverityandglucidicmarkerswithapremilastacasereport AT campionee smallmoleculesbigpromisesimprovementofpsoriasisseverityandglucidicmarkerswithapremilastacasereport
_version_	1718399756637569024

Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report

Ejemplares similares